Overview

Chinese Multiple Dose Escalation (MDE) High Dose Study

Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Overweight/Obese Subjects with Chinese ancestry with Type 2 Diabetes Mellitus
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca